Isentress raltegravir: Phase II data

In an ongoing, double-blind Phase II trial in 198 treatment-naïve patients, twice-daily doses of oral Isentress reduced HIV viral loads to <50 copies/mL in 78% of 160 patients after 144 weeks compared...